AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24993981 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2912
Study 24993981 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-selective β-blockers
Number of subjects: 2912
Study 23081934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pine nut allergens (albumin and vicilin)
Number of subjects: 10
Study 20887614 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin therapy
Number of subjects: 5010
Study 17922448 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 15793108 — intervention group
Group type: COMPARATOR
Intervention: Bolus injection of 1 g every 8 h for 24 h
Number of subjects: 9
Study 15793108 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-h infusion of 1 g every 8 h for 24 h
Number of subjects: 9
Study 15793108 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-h infusion of 2 g every 8 h for 24 h
Number of subjects: 9
Study 11902505 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy
Number of subjects: 0
Study 11902505 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care
Number of subjects: 0
Study 11902505 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care programmes
Number of subjects: 0
Study 11789238 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenmai injection (intravenous for 7 days)
Number of subjects: 80
Study 11789238 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Shenmai injection)
Number of subjects: 80
Study 8815119 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy
Number of subjects: 40
Study 8815119 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 40
Study 1504127 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 0
Study 1504127 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional measures (mortality, morbidity, side effects)
Number of subjects: 0
Study 6091245 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchrodyn 1‐17, 100 micrograms i.m. a day for 15 consecutive days
Number of subjects: 90
Study 6091245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 6091245 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchrodyn 1‐17
Number of subjects: 90
Study 6091245 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol circadian rhythm study
Number of subjects: 90
Study 31528849 — intervention group
Group type: EXPERIMENTAL
Intervention: High-flow nasal cannulae (HFNC)
Number of subjects: 100
Study 31528849 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 100
Study 30024544 — intervention group
Group type: EXPERIMENTAL
Intervention: Maekmoondong‐tang
Number of subjects: 96
Study 30024544 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 27417705 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40mg orally 2 hours prior to surgery
Number of subjects: 40
Study 27417705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 26029978 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinach extract rich in thylakoids
Number of subjects: 60
Study 26029978 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23943316 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferoxamine (DFO) at 62 mg/kg/day (up to a maximum daily dose of 6000 mg/day)
Number of subjects: 324
Study 23943316 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 324
Study 21428978 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortexolone 17α-propionate 1% cream
Number of subjects: 77
Study 21428978 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 77
Study 21428978 — intervention group
Group type: COMPARATOR
Intervention: Tretinoin 0·05% cream
Number of subjects: 77
Study 18971897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproheptadine
Number of subjects: 29
Study 18971897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 16490350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) at 1.2 bar/250 cycles/min
Number of subjects: 10
Study 16490350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) at 1.2 bar/350 cycles/min
Number of subjects: 10
Study 16490350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) at 1.8 bar/350 cycles/min
Number of subjects: 10
Study 16490350 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation (IPV) at 1.8 bar/250 cycles/min
Number of subjects: 10
Study 16490350 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation (PSV)
Number of subjects: 10
Study 16490350 — intervention group
Group type: COMPARATOR
Intervention: Prolonged apnea trial in normal subjects
Number of subjects: 10
Study 15017644 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative treatment (gastroenterologist and psychologist working together)
Number of subjects: 41
Study 15017644 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment directed at gastrointestinal function
Number of subjects: 41
Study 15017644 — intervention group
Group type: COMPARATOR
Intervention: Psychological therapy
Number of subjects: 41
Study 11051309 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert system (PI) assistance during the experiment
Number of subjects: 12
Study 11051309 — intervention group
Group type: COMPARATOR
Intervention: No expert system assistance (control)
Number of subjects: 12
Study 9351621 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide dry powder, 800 microg twice daily, delivered from a Turbuhaler
Number of subjects: 55
Study 9351621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 8463867 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (312 mumol of vitamin A as retinyl palmitate)
Number of subjects: 153
Study 8463867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 153
Study 3543579 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerosis
Number of subjects: 0
Study 3543579 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 29607764 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative rehabilitation programs
Number of subjects: 0
Study 27929727 — intervention group
Group type: COMPARATOR
Intervention: Patching alone (Group A - control)
Number of subjects: 40
Study 27929727 — intervention group
Group type: EXPERIMENTAL
Intervention: Action video games with patching (Group B - study)
Number of subjects: 40
Study 24449241 — intervention group
Group type: EXPERIMENTAL
Intervention: VMPT-VT (Bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance)
Number of subjects: 511
Study 24449241 — intervention group
Group type: COMPARATOR
Intervention: VMP (Bortezomib-melphalan-prednisone)
Number of subjects: 511
Study 21899797 — intervention group
Group type: EXPERIMENTAL
Intervention: Natto and viscous vegetables breakfast
Number of subjects: 11
Study 21899797 — intervention group
Group type: COMPARATOR
Intervention: Control meal (WR with non-viscous boiled soyabeans, potatoes, and broccoli)
Number of subjects: 11
Study 21403595 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity whole body vibration (15 mins, 30 Hz, 0.3 g)
Number of subjects: 47
Study 21403595 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity whole body vibration (2 × 3 mins, 12.5 Hz, 1 g)
Number of subjects: 47
Study 21403595 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vibration)
Number of subjects: 47
Study 21403595 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body vibration groups (both low and high intensity)
Number of subjects: 47
Study 18602742 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation treatment (ART) with 60 Gray (Gy)
Number of subjects: 0
Study 18602742 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation treatment (ART) with 60-64 Gy
Number of subjects: 0
Study 18602742 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant radiation treatment (ART)
Number of subjects: 0
Study 18602742 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ART)
Number of subjects: 0
Study 16645533 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate (NOMAc; 5 mg/day for 10 days x month for 12 months) plus calcium (1 g/day)
Number of subjects: 36
Study 16645533 — intervention group
Group type: COMPARATOR
Intervention: Calcium alone
Number of subjects: 36
Study 12819322 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitor (ramipril)
Number of subjects: 0
Study 12819322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydropyridine calcium channel blocker (amlodipine)
Number of subjects: 0
Study 12819322 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blocker (metoprolol)
Number of subjects: 0
Study 12819322 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower BP control goal (mean arterial pressure ≤ 92 mmHg)
Number of subjects: 0
Study 12819322 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual BP control goal (mean arterial pressure 102 to 107 mmHg inclusive)
Number of subjects: 0
Study 12819322 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite outcome (reduction in GFR by 50%, end-stage renal disease, or death)
Number of subjects: 0
Study 10992315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cavalieri method of modern design stereology with MRI
Number of subjects: 12
Study 10992315 — intervention group
Group type: COMPARATOR
Intervention: Control group (five controls)
Number of subjects: 12
Study 8795307 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic infusion via the brachial vein (Group S)
Number of subjects: 40
Study 8795307 — intervention group
Group type: COMPARATOR
Intervention: Ipsipedal infusion via the dorsalis pedis vein (Group IP)
Number of subjects: 40
Study 7936824 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetuses with hemolytic disease (n = 15)
Number of subjects: 41
Study 7936824 — intervention group
Group type: COMPARATOR
Intervention: Control fetuses (n = 26)
Number of subjects: 41
Study 3217807 — intervention group
Group type: EXPERIMENTAL
Intervention: Vindesine (VDS) 4 mg/m2 IV weekly X 8, then every second week
Number of subjects: 259
Study 3217807 — intervention group
Group type: EXPERIMENTAL
Intervention: Lomustine (CCNU) 70 mg/m2 orally, cyclophosphamide (CTX) 1000 mg/m2 IV every 4 weeks, methotrexate (MTX) 20 mg/m2 orally days 15 and 18 of each course
Number of subjects: 259
Study 3217807 — intervention group
Group type: EXPERIMENTAL
Intervention: CCNU + CTX + MTX + VDS (lower doses: CCNU 50 mg/m2, CTX 750 mg/m2, VDS 2 mg/m2)
Number of subjects: 259
Study 29875101 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day quizartinib
Number of subjects: 76
Study 29875101 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg/day quizartinib
Number of subjects: 76
Study 26150601 — intervention group
Group type: EXPERIMENTAL
Intervention: SB4 (50 mg subcutaneous weekly)
Number of subjects: 596
Study 26150601 — intervention group
Group type: COMPARATOR
Intervention: ETN (50 mg subcutaneous weekly)
Number of subjects: 596
Study 26150601 — intervention group
Group type: EXPERIMENTAL
Intervention: SB4
Number of subjects: 596
Study 26150601 — intervention group
Group type: COMPARATOR
Intervention: ETN
Number of subjects: 596
Study 26776356 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant patch (FSP; TachoSil)
Number of subjects: 224
Study 26776356 — intervention group
Group type: COMPARATOR
Intervention: Oxidized regenerated cellulose gauze (ORCG; Surgicel Original)
Number of subjects: 224
Study 24106918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification - Interpretation (CBM-I) in Positive condition
Number of subjects: 89
Study 24106918 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 89
Study 21850615 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial approach (TRA) for primary PCI
Number of subjects: 108
Study 21850615 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral approach (TFA) with StarClose for primary PCI
Number of subjects: 108
Study 19494176 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electroacupuncture (n = 9)
Number of subjects: 20
Study 19494176 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise (n = 5)
Number of subjects: 20
Study 19494176 — intervention group
Group type: COMPARATOR
Intervention: Untreated control (n = 6)
Number of subjects: 20
Study 17919618 — intervention group
Group type: COMPARATOR
Intervention: Tacrolimus monotherapy (MONO)
Number of subjects: 58
Study 17919618 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus combination therapy (COMBO)
Number of subjects: 58
Study 15157791 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg ethinylestradiol plus 150 microg desogestrel (20EE/DSG)
Number of subjects: 998
Study 15157791 — intervention group
Group type: COMPARATOR
Intervention: 20 microg ethinylestradiol plus 100 microg levonorgestrel (20EE/LNG)
Number of subjects: 998
Study 11536349 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapist led workshop
Number of subjects: 45
Study 11536349 — intervention group
Group type: COMPARATOR
Intervention: Booklet
Number of subjects: 45
Study 11536349 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 11536349 — intervention group
Group type: EXPERIMENTAL
Intervention: Workshop
Number of subjects: 45
Study 9764968 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA (4 mg kg(‐1) h(‐1) continuous infusion with a front loaded bolus of 4 mg kg(‐1))
Number of subjects: 10
Study 9764968 — intervention group
Group type: COMPARATOR
Intervention: Placebo (volume matched)
Number of subjects: 10
Study 8556026 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior modification‐based (BM) weight reduction intervention
Number of subjects: 156
Study 8556026 — intervention group
Group type: COMPARATOR
Intervention: Food addiction theory‐based (FD) weight reduction intervention
Number of subjects: 156
Study 2238184 — intervention group
Group type: COMPARATOR
Intervention: 0 mg bendrofluazide
Number of subjects: 257
Study 2238184 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg bendrofluazide
Number of subjects: 257
Study 2238184 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg bendrofluazide
Number of subjects: 257
Study 2238184 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0 mg bendrofluazide
Number of subjects: 257
Study 2238184 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg bendrofluazide
Number of subjects: 257
Study 360764 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral norephedrine
Number of subjects: 100
Study 360764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30691153 — intervention group
Group type: EXPERIMENTAL
Intervention: Swimming training (12 weeks, 3 times per week, 60 min/session)
Number of subjects: 0
Study 30691153 — intervention group
Group type: COMPARATOR
Intervention: Sedentary controls
Number of subjects: 0
Study 28697099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nutrition counseling intervention by a registered dietitian throughout pregnancy and 6 months postpartum
Number of subjects: 300
Study 28697099 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive nutrition counseling intervention
Number of subjects: 300
Study 26363720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone 20-60 mg or 80-120 mg
Number of subjects: 416
Study 26363720 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurasidone (continuation treatment)
Number of subjects: 416
Study 26363720 — intervention group
Group type: COMPARATOR
Intervention: Placebo (switched to lurasidone)
Number of subjects: 416
Study 24108252 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (0-80 mg)
Number of subjects: 14
Study 24108252 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine (doses >40 mg)
Number of subjects: 14
Study 24108252 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Number of subjects: 14
Study 21382516 — intervention group
Group type: EXPERIMENTAL
Intervention: Community Care (CC) - 6 month SDT-based intervention
Number of subjects: 0
Study 21382516 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended Need Support (ENS) - 12 month SDT-based intervention
Number of subjects: 0
Study 21382516 — intervention group
Group type: EXPERIMENTAL
Intervention: Harm Reduction (HR) - Extended need support with medication recommendation
Number of subjects: 0
Study 21382516 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 21382516 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary outcome
Number of subjects: 0
Study 21382516 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 0
Study 18974068 — intervention group
Group type: EXPERIMENTAL
Intervention: Activator-headgear appliance for at least 9 months followed by fixed appliance therapy
Number of subjects: 64
Study 18974068 — intervention group
Group type: COMPARATOR
Intervention: Minor orthodontic treatment (control group)
Number of subjects: 64
Study 16724576 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg vardenafil plus 0.5 g/kg ethanol
Number of subjects: 12
Study 16724576 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol plus placebo
Number of subjects: 12
Study 16724576 — intervention group
Group type: COMPARATOR
Intervention: Vardenafil plus placebo
Number of subjects: 12
Study 14606098 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Vitamin C (10 g/day) intravenously for 5 days
Number of subjects: 84
Study 14606098 — intervention group
Group type: COMPARATOR
Intervention: Low-dose Vitamin C (1 g/day) intravenously for 5 days
Number of subjects: 84
Study 10779882 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 0
Study 10779882 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 2024983 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin for 24 weeks
Number of subjects: 251
Study 2024983 — intervention group
Group type: COMPARATOR
Intervention: Vehicle-treated control
Number of subjects: 251
Study 2024983 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% tretinoin therapy
Number of subjects: 251
Study 6941460 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinidazole
Number of subjects: 43
Study 6941460 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 43
Study 31056218 — intervention group
Group type: COMPARATOR
Intervention: Drug (exact dosage and duration not specified)
Number of subjects: 0
Study 31056218 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28319853 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal challenge (500/1000/1500 kcal)
Number of subjects: 14
Study 28319853 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal challenge (1500 kcal)
Number of subjects: 14
Study 28319853 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal challenge
Number of subjects: 14
Study 27098321 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted unicompartmental knee arthroplasty
Number of subjects: 139
Study 27098321 — intervention group
Group type: COMPARATOR
Intervention: Conventional unicompartmental knee arthroplasty
Number of subjects: 139
Study 27098321 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted femoral component sagittal position
Number of subjects: 139
Study 27098321 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted femoral component coronal position
Number of subjects: 139
Study 27098321 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted femoral component axial position
Number of subjects: 139
Study 27098321 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted tibial component sagittal position
Number of subjects: 139
Study 27098321 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted tibial component axial position
Number of subjects: 139
Study 25041339 — intervention group
Group type: EXPERIMENTAL
Intervention: basiliximab + belatacept high dose (HD) + mycophenolate mofetil (MMF)
Number of subjects: 260
Study 25041339 — intervention group
Group type: EXPERIMENTAL
Intervention: belatacept HD + MMF
Number of subjects: 260
Study 25041339 — intervention group
Group type: EXPERIMENTAL
Intervention: belatacept low dose (LD) + MMF
Number of subjects: 260
Study 25041339 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus + MMF
Number of subjects: 260
Study 25041339 — intervention group
Group type: EXPERIMENTAL
Intervention: tacrolimus alone
Number of subjects: 260
Study 25041339 — intervention group
Group type: EXPERIMENTAL
Intervention: belatacept (all groups)
Number of subjects: 260
Study 25041339 — intervention group
Group type: EXPERIMENTAL
Intervention: belatacept HD
Number of subjects: 260
Study 25041339 — intervention group
Group type: COMPARATOR
Intervention: basiliximab + belatacept HD
Number of subjects: 260
Study 25041339 — intervention group
Group type: COMPARATOR
Intervention: tacrolimus
Number of subjects: 260
Study 22297244 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 10mg once daily (n=277)
Number of subjects: 416
Study 22297244 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=139)
Number of subjects: 416
Study 20206844 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 1 microg/kg
Number of subjects: 160
Study 20206844 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 2 microg/kg
Number of subjects: 160
Study 17372025 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass pollen immunotherapy (Phleum pratense)
Number of subjects: 44
Study 17372025 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-IT IgA fractions
Number of subjects: 44
Study 16279148 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (specific dosage and duration not mentioned)
Number of subjects: 2520
Study 16279148 — intervention group
Group type: EXPERIMENTAL
Intervention: Summary of study results sent to primary care physicians
Number of subjects: 2520
Study 11897644 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial liquid ventilation (PLV) with perflubron
Number of subjects: 90